Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Príomhchruthaitheoirí: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
Elsevier
2019
|
Achoimre: |
---|